Enhanced immune reconstitution with albuvirtide in HIV-infected immunological non-responders

Lina Fan, Yue Hu, Rui Li, Jiaqi Ding, Yuan-Tao Liu, Shuchang Yu, Min Hu, Rui Su, Yangyang Li, Aiping Yu, Dong Xie, Qingxia Zhao, Ping MaFrontiers in Cellular and Infection Microbiology 2024 · DOI

Abstract

Significant CD4<sup>+</sup>T cell count increase suggests ABT enhances immune function in INRs which may be attributed to its antiviral properties as well as its ability to increase thymic cell output and decrease cell apoptosis.

Introduction

While modern antiretroviral therapy (ART) is highly effective at suppressing HIV replication, a significant portion of patients—roughly 20–30% in China—are classified as immunological non-responders (INRs). These individuals achieve an "undetectable" viral load, yet their CD4+ T cell counts remain stubbornly low (typically <350 cells/µL). This incomplete immune reconstitution is a major clinical hurdle, leaving patients at higher risk for AIDS-related complications, cardiovascular disease, and premature aging.

This study investigates whether adding Albuvirtide (ABT), a long-acting HIV fusion inhibitor, to standard ART can "jumpstart" the immune systems of these patients. The researchers found that ABT doesn't just suppress the virus; it appears to enhance immune recovery by increasing the output of new T cells from the thymus and protecting existing cells from programmed death (apoptosis).

Methodology

The researchers conducted a prospective, open-label, controlled clinical study involving 50 INR patients. Participants were split 1:1 into two groups: the control group maintained their original ART regimen, while the "intensive group" received supplemental Albuvirtide (320 mg IV daily for the first three days, followed by weekly injections for 12 weeks).

Figure 1: Flow diagrams showing the sample populations enrolled in the clinical (A) and cytological (B) studies.

Clinical monitoring of CD4+ and CD8+ T cell counts occurred at baseline, week 12, and week 24. To understand the underlying mechanisms, the team performed cytological analysis on blood specimens from a subset of participants, using flow cytometry and immunofluorescence to examine specific T cell subsets, markers of thymic output (CD45RA+CD31+), cell apoptosis (caspase-3), and autophagy (MDC). These were compared against 6 Healthy Donors (HDs) and 5 Immunological Responders (IRs).

Key Insights and Ideas

  • Beyond Viral Suppression: ABT’s benefit may extend beyond its role as an antiviral. While all patients had suppressed viral loads, only the ABT group saw significant CD4+ gains, suggesting a direct or indirect immunomodulatory effect.
  • Thymic Rejuvenation: Patients with a "satisfactory" response to ABT had higher levels of naive CD4+ T cells. This suggests that ABT might help the thymus—the organ responsible for T cell production—function more effectively, even in older patients.
  • The Apoptosis Shield: ABT treatment was associated with a significant decrease in T cells expressing caspase-3, a key marker of apoptosis (cell suicide). By preventing premature cell death, ABT helps maintain a higher T cell reservoir.
  • Age-Specific Benefits: Interestingly, patients over 45 years old showed a more prominent response to ABT intensification compared to younger cohorts, which is notable given that thymic function naturally declines with age.

Key Results

  • CD4+ Count Increase: At week 12, the ABT group saw a mean increase of 45 cells/µL, while the control group saw a slight decline of -5 cells/µL ($p < 0.001$).
  • Sustained Gains: Even after discontinuing ABT at week 12, the intensive group maintained higher CD4+ counts at week 24 (a net gain of 55 cells/µL from baseline vs. -5 in the control group, $p = 0.012$).
  • Responder Rate: 40% of the ABT group achieved a "significant" immune response (defined as an increase of $\ge 100$ cells/µL or $>30\%$ from baseline) compared to only 8% in the control group.
  • Safety: The treatment was well-tolerated. The most common laboratory abnormality was a manageable increase in triglycerides (16% of the ABT group).

Limitations and Future Work

The authors acknowledge several limitations, including the relatively small sample size (n=50) and the non-randomized design, as participants were assigned based on their ability to adhere to the weekly IV schedule. Furthermore, the 24-week follow-up is short for assessing long-term immune health. Future studies should involve larger, randomized cohorts and explore the exact molecular pathways by which fusion inhibitors trigger these systemic immune changes.

Summary updated

Abstract

Significant CD4<sup>+</sup>T cell count increase suggests ABT enhances immune function in INRs which may be attributed to its antiviral properties as well as its ability to increase thymic cell output and decrease cell apoptosis.
BibTeX
@inproceedings{fan2024enhanced,
  author = {Lina Fan and Yue Hu and Rui Li and Jiaqi Ding and Yuan-Tao Liu and Shuchang Yu and Min Hu and Rui Su and Yangyang Li and Aiping Yu and Dong Xie and Qingxia Zhao and Ping Ma},
  title = {{Enhanced immune reconstitution with albuvirtide in HIV-infected immunological non-responders}},
  booktitle = {Frontiers in Cellular and Infection Microbiology},
  year = {2024},
  doi = {10.3389/fcimb.2024.1397743},
}
Figure